Metabolomics provides powerful tools that can inform about heterogeneity in disease and response to treatments. In this study, we employed an electrochemistry-based targeted metabolomics platform to assess the metabolic effects of three randomly-assigned treatments: escitalopram, duloxetine, and Cognitive Behavior Therapy (CBT) in 163 treatment-naïve outpatients with major depressive disorder. Serum samples from baseline and 12 weeks post-treatment were analyzed using targeted liquid chromatography-electrochemistry for metabolites related to tryptophan, tyrosine metabolism and related pathways. Changes in metabolite concentrations related to each treatment arm were identified and compared to define metabolic signatures of exposure. In addition, association between metabolites and depressive symptom severity (assessed with the 17-item Hamilton Rating Scale for Depression [HRSD₁₇]) and anxiety symptom severity (assessed with the 14-item Hamilton Rating Scale for Anxiety [HRSA₁₄]) were evaluated, both at baseline and after 12 weeks of treatment.

中文翻译：

---

5-羟色胺再摄取抑制剂（艾司西酞普兰）、5-羟色胺去甲肾上腺素再摄取抑制剂（度洛西汀）的代谢组学特征以及重度抑郁症关键神经递质通路的认知行为疗法

代谢组学提供了强大的工具，可以了解疾病的异质性和治疗反应。在这项研究中，我们采用基于电化学的靶向代谢组学平台来评估三种随机分配的治疗方法：艾司西酞普兰、度洛西汀和认知行为疗法 (CBT) 对 163 名未接受过治疗的重度抑郁症门诊患者的代谢影响。使用靶向液相色谱-电化学分析基线和治疗后 12 周的血清样本，分析与色氨酸、酪氨酸代谢和相关途径相关的代谢物。确定并比较与每个治疗组相关的代谢物浓度的变化，以确定暴露的代谢特征。此外，还评估了代谢物与抑郁症状严重程度（使用 17 项汉密尔顿抑郁评定量表 [HRSD ₁₇ ] 评估）和焦虑症状严重程度（使用 14 项汉密尔顿焦虑评定量表 [HRSA ₁₄ ] 评估）之间的关联。 ，在基线时和治疗 12 周后。